Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationJ. Pharm. Pharmacol. 2007, 59(5):629-35
AbstractDelivery of steroids to the retina is currently undertaken with invasive injections into the vitreous cavity. This paper describes a non-invasive method to deliver steroids in therapeutic levels to the retina in rabbits. Dexamethasone was formulated as somewhat water-soluble dexamethasone/gamma-cyclodextrin (gammaCD) microparticles in a low-viscosity aqueous eye drop suspension. The mean (+/-standard deviation) diameter of the particles was 20.4+/-10.3 microm, with no particles larger than 60 microm. The aqueous suspension formulation was tested in rabbits and compared with an aqueous dexamethasone eye drop solution containing randomly methylated beta-cyclodextrin (RMbetaCD). The dexamethasone concentration was identical in both formulations (15 mg mL(-1)). The drug was administered to the left eye but determined in both eyes. The amount reaching different eye tissues via the topical route was determined by subtracting the amount found in the right eye from the amount found in the left eye. Two hours after single application of the dexamethasone/gammaCD eye drops to rabbits the mean (+/-s.d.) concentration in vitreous was 29+/-16 ng g(-1), 86% of which reached vitreous via the topical route and in retina the concentration was 57+/-22 ng g(-1) (49% via topical route). For the RMbetaCD the values were 22.6+/-9 and 66+/-49 ng g(-1) (73 and 14% via topical route), respectively. These steroid levels are comparable with the dexamethasone concentration achieved 1 month after intravitreal injection. The aqueous dexamethasone/gammaCD eye drop formulation was chemically stable during 7 months storage and well tolerated with no visible short-term side effects.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
- Authors: Sigurdsson HH, Konráethsdóttir F, Loftsson T, Stefánsson E
- Issue date: 2007 Sep
- Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans.
- Authors: Kristinsson JK, Fridriksdóttir H, Thórisdóttir S, Sigurdardóttir AM, Stefánsson E, Loftsson T
- Issue date: 1996 May
- Dexamethasone eye drops containing γ-cyclodextrin-based nanogels.
- Authors: Moya-Ortega MD, Alves TF, Alvarez-Lorenzo C, Concheiro A, Stefánsson E, Thorsteinsdóttir M, Loftsson T
- Issue date: 2013 Jan 30
- Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
- Authors: Jansook P, Stefánsson E, Thorsteinsdóttir M, Sigurdsson BB, Kristjánsdóttir SS, Bas JF, Sigurdsson HH, Loftsson T
- Issue date: 2010 Oct
- Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
- Authors: Wang S, Li D, Ito Y, Nabekura T, Wang S, Zhang J, Wu C
- Issue date: 2004 Jul